• Explore /
  • Poster
  • / Gemcitabine (Gem) and nab-paclitaxel (NP) ± nivolumab (nivo) ± CD40 agonistic monoclonal antibody APX005M (Sotigalimab), in patients (Pts) with untreated metastatic pancreatic adenocarcinoma (mPDAC): Phase (Ph) 2 final results.

Gemcitabine (Gem) and nab-paclitaxel (NP) ± nivolumab (nivo) ± CD40 agonistic monoclonal antibody APX005M (Sotigalimab), in patients (Pts) with untreated metastatic pancreatic adenocarcinoma (mPDAC): Phase (Ph) 2 final results.

Abstract Video & Slides Poster

Authors

null

Mark H. O'Hara

University of Pennsylvania Abramson Cancer Center, Philadelphia, PA

Mark H. O'Hara , Eileen Mary O'Reilly , Robert A. Wolff , Zev A. Wainberg , Andrew H. Ko , Osama E. Rahma , George A. Fisher Jr., Jaclyn Paige Lyman , Christopher R. Cabanski , Joyson Joseph Karakunnel , Pier Federico Gherardini , Lacey J. Kitch , Samantha Bucktrout , Elizabeth Christopher , Rosemarie Mick , Richard Chen , Ovidiu C. Trifan , Lisa Salvador , Jill O'Donnell-Tormey , Robert H. Vonderheide

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2021 ASCO Annual Meeting

Session Type

Poster Discussion Session

Session Title

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Track

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Sub Track

Pancreatic Cancer

Clinical Trial Registration Number

NCT03214250

Citation

J Clin Oncol 39, 2021 (suppl 15; abstr 4019)

DOI

10.1200/JCO.2021.39.15_suppl.4019

Abstract #

4019

Abstract Disclosures

Similar Posters

First Author: Jaclyn P. Lyman

First Author: Dong-Sheng Zhang

First Author: Gang Jin

First Author: Manish Sharma